In U2OS cells, azithromycin increased eIF2α Ser51 phosphorylation after 16 hours at 10–40 μM. This cellular stress-response endpoint does not establish therapeutic efficacy. [2]
In U2OS tandem RFP-GFP-LC3 reporter cells, azithromycin increased the autophagic-flux inhibition score after 6 hours at 10–40 μM. Increased LC3 puncta should therefore not be interpreted as increased completion of autophagy. [2]
Azithromycin binding in a 70S ribosomal crystal complex
Biochemical assay · Thermus thermophilus HB8 70S ribosome crystals [1]
A single azithromycin binding site was modeled in the exit tunnel. The observed orientation resembles the compared archaeal complex and disagrees with an earlier bacterial structural model.
Literature-Reported Treatment Conditions
- Treatment concentration
- 500 μM crystal-soaking concentration
- Exposure duration
- Overnight
- Method
- Soaking into cryostabilized ribosome crystals
- Reported limits
- Azithromycin supplier, lot and hydrate/salt form are not specified in the read main methods; soaking concentration is not an IC50.
Methods and source locations
Compound reported in the paper: Azithromycin; Compound label in the paper: Azithromycin
Evidence for the named azithromycin material in this model; no Adooq lot validation, hydrate equivalence or salt conversion.
Fig. 2D–F; Results: Azithromycin; Materials and Methods
Bound azithromycin in the 70S ribosomal complex: X-ray crystallography with unbiased Fo−Fc difference electron density and structural overlays — Fig. 2D–F and caption; Azithromycin subsection
Azithromycin-induced eIF2α phosphorylation
Cell-based study · Human U2OS osteosarcoma cells [2]
Azithromycin increased the cytoplasmic phospho-eIF2α signal relative to vehicle. Tunicamycin and thapsigargin served as positive controls. Other ER-stress reporters in Fig. 2 showed smaller responses than positive controls; the selected endpoint is phosphorylation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10, 20, 40 μM
- Exposure duration
- 16 h
- Method
- Azithromycin alone; comparator positive controls: tunicamycin or thapsigargin, each 3 μM
- Co-treatment
- No azithromycin combination in the adopted experiment
- Reported limits
- Caption identifies vehicle control but solvent identity is not specified in the read methods; no exact numerical intensity inferred from bars.
Methods and source locations
Compound reported in the paper: Azithromycin; Compound label in the paper: AZT
Evidence for the named azithromycin material in this model; no Adooq lot validation, hydrate equivalence or salt conversion.
Fig. 2A,B; Results first subsection; Cell culture and chemicals; Immunofluorescence
Cytoplasmic eIF2α Ser51 phosphorylation: Phosphoepitope-specific immunofluorescence; automated microscopy — Fig. 2A,B and caption; Immunofluorescence; Statistical analysis
Azithromycin inhibition of autophagic flux
Cell-based study · Human U2OS cells expressing tandem RFP-GFP-LC3 [2]
Azithromycin increased the autophagic-flux inhibition score relative to vehicle. Torin 1 and bafilomycin A1 supplied induction and flux-inhibition comparator controls. The reporter readout distinguishes punctum accumulation from productive degradation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10, 20, 40 μM
- Exposure duration
- 6 h
- Method
- Azithromycin alone; controls include torin 1 (300 nM) and bafilomycin A1 (100 nM)
- Co-treatment
- No azithromycin combination in the adopted experiment
- Reported limits
- Vehicle solvent not specified in the read methods; exact score values not tabulated in the inspected evidence and not estimated from bars.
Methods and source locations
Compound reported in the paper: Azithromycin; Compound label in the paper: AZT
Evidence for the named azithromycin material in this model; no Adooq lot validation, hydrate equivalence or salt conversion.
Supplemental Fig. S2A,B and S2 legend; Results first subsection; Cell culture and chemicals; High-content microscopy
RFP+GFP+ and RFP+GFP− LC3 puncta used to calculate flux inhibition: Tandem fluorescent LC3 reporter microscopy after fixation — Supplemental Fig. S2A,B and S2 legend; High-content microscopy